The University of Southampton
University of Southampton Institutional Repository

Distinct neutralising and complement-fixing antibody responses can be induced to the same antigen in haemodialysis patients after immunisation with different vaccine platforms

Distinct neutralising and complement-fixing antibody responses can be induced to the same antigen in haemodialysis patients after immunisation with different vaccine platforms
Distinct neutralising and complement-fixing antibody responses can be induced to the same antigen in haemodialysis patients after immunisation with different vaccine platforms

Background/objectives: generalised immune dysfunction in chronic kidney disease, especially in patients requiring haemodialysis (HD), significantly enhances the risk of severe infections. Vaccine-induced immunity is typically reduced in HD populations. The SARS-CoV-2 pandemic provided an opportunity to examine the magnitude and functionality of antibody responses in HD patients to a previously unencountered antigen-Spike (S)-glycoprotein-after vaccination with different vaccine platforms (viral vector (VV); mRNA (mRV)). 

Methods: we compared the total and functional anti-S antibody responses (cross-variant neutralisation and complement binding) in 187 HD patients and 43 healthy controls 21-28 days after serial immunisation. 

Results: after 2 doses of the same vaccine, HD patients had anti-S antibody levels and a complement binding capacity comparable to controls. However, 2 doses of mRV induced greater polyfunctional antibody responses than VV (defined by the presence of both complement binding and cross-variant neutralisation activity). Interestingly, an mRV boost after 2 doses of VV significantly enhanced antibody functionality in HD patients without a prior history of SARS-CoV-2 infection.

 Conclusions: HD patients can generate near-normal, functional antigen-specific antibody responses following serial vaccination to a novel antigen. Encouragingly, exploiting immunological memory by using mRNA vaccines and boosting may improve the success of vaccination strategies in this vulnerable patient population.

2076-393X
Wall, Nadezhda
41f7835f-a770-4454-9999-045b7704b9e0
Lamerton, Rachel
02c5bf93-80b1-4fee-b676-f22007a19096
Ashford, Fiona
df47a443-a2f4-4149-9005-59cb88af060e
Perez-Toledo, Marisol
db9dfcc0-d3a0-4c9d-9606-f2370574e3d3
Jasiulewicz, Aleksandra
b30ee70d-f329-4ce1-8ebd-a95681467bca
Banham, Gemma D.
60af2906-a005-4477-a328-be6ba8283ba1
Newby, Maddy L.
417cba47-6a6f-42b9-8b9c-640f0518c621
Faustini, Sian E.
fc25e886-bb2c-4c9c-a421-df8e00e6b1ba
Richter, Alex G.
a8d5bc53-c51b-463d-af6b-ca8b8a5412d0
Selvaskandan, Haresh
876ba5a0-35ac-458c-954d-e8476e9c6503
Billany, Roseanne E.
0a4a773b-8d2e-4309-91cc-c352537b8a37
Adenwalla, Sherna F.
ca459660-8a14-4df8-873d-bf633d91c343
Henderson, Ian R.
13c783ad-9d21-4787-bab4-32ea5034346e
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Graham-Brown, Matthew
994badbf-d625-4331-9438-ae50a8ef1c14
Harper, Lorraine
cf828052-41a4-46f3-b451-8e070a9e32c5
Cunningham, Adam F.
63973765-dcc3-4a66-bd15-e0d774484b74
Wall, Nadezhda
41f7835f-a770-4454-9999-045b7704b9e0
Lamerton, Rachel
02c5bf93-80b1-4fee-b676-f22007a19096
Ashford, Fiona
df47a443-a2f4-4149-9005-59cb88af060e
Perez-Toledo, Marisol
db9dfcc0-d3a0-4c9d-9606-f2370574e3d3
Jasiulewicz, Aleksandra
b30ee70d-f329-4ce1-8ebd-a95681467bca
Banham, Gemma D.
60af2906-a005-4477-a328-be6ba8283ba1
Newby, Maddy L.
417cba47-6a6f-42b9-8b9c-640f0518c621
Faustini, Sian E.
fc25e886-bb2c-4c9c-a421-df8e00e6b1ba
Richter, Alex G.
a8d5bc53-c51b-463d-af6b-ca8b8a5412d0
Selvaskandan, Haresh
876ba5a0-35ac-458c-954d-e8476e9c6503
Billany, Roseanne E.
0a4a773b-8d2e-4309-91cc-c352537b8a37
Adenwalla, Sherna F.
ca459660-8a14-4df8-873d-bf633d91c343
Henderson, Ian R.
13c783ad-9d21-4787-bab4-32ea5034346e
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Graham-Brown, Matthew
994badbf-d625-4331-9438-ae50a8ef1c14
Harper, Lorraine
cf828052-41a4-46f3-b451-8e070a9e32c5
Cunningham, Adam F.
63973765-dcc3-4a66-bd15-e0d774484b74

Wall, Nadezhda, Lamerton, Rachel, Ashford, Fiona, Perez-Toledo, Marisol, Jasiulewicz, Aleksandra, Banham, Gemma D., Newby, Maddy L., Faustini, Sian E., Richter, Alex G., Selvaskandan, Haresh, Billany, Roseanne E., Adenwalla, Sherna F., Henderson, Ian R., Crispin, Max, Graham-Brown, Matthew, Harper, Lorraine and Cunningham, Adam F. (2024) Distinct neutralising and complement-fixing antibody responses can be induced to the same antigen in haemodialysis patients after immunisation with different vaccine platforms. Vaccines, 13 (1), [7]. (doi:10.3390/vaccines13010007).

Record type: Article

Abstract

Background/objectives: generalised immune dysfunction in chronic kidney disease, especially in patients requiring haemodialysis (HD), significantly enhances the risk of severe infections. Vaccine-induced immunity is typically reduced in HD populations. The SARS-CoV-2 pandemic provided an opportunity to examine the magnitude and functionality of antibody responses in HD patients to a previously unencountered antigen-Spike (S)-glycoprotein-after vaccination with different vaccine platforms (viral vector (VV); mRNA (mRV)). 

Methods: we compared the total and functional anti-S antibody responses (cross-variant neutralisation and complement binding) in 187 HD patients and 43 healthy controls 21-28 days after serial immunisation. 

Results: after 2 doses of the same vaccine, HD patients had anti-S antibody levels and a complement binding capacity comparable to controls. However, 2 doses of mRV induced greater polyfunctional antibody responses than VV (defined by the presence of both complement binding and cross-variant neutralisation activity). Interestingly, an mRV boost after 2 doses of VV significantly enhanced antibody functionality in HD patients without a prior history of SARS-CoV-2 infection.

 Conclusions: HD patients can generate near-normal, functional antigen-specific antibody responses following serial vaccination to a novel antigen. Encouragingly, exploiting immunological memory by using mRNA vaccines and boosting may improve the success of vaccination strategies in this vulnerable patient population.

Text
vaccines-13-00007 - Version of Record
Available under License Creative Commons Attribution.
Download (2MB)

More information

Accepted/In Press date: 16 December 2024
Published date: 25 December 2024

Identifiers

Local EPrints ID: 503255
URI: http://eprints.soton.ac.uk/id/eprint/503255
ISSN: 2076-393X
PURE UUID: f52d0979-4903-4a02-9832-d528032e83a2
ORCID for Max Crispin: ORCID iD orcid.org/0000-0002-1072-2694

Catalogue record

Date deposited: 25 Jul 2025 16:38
Last modified: 22 Aug 2025 02:19

Export record

Altmetrics

Contributors

Author: Nadezhda Wall
Author: Rachel Lamerton
Author: Fiona Ashford
Author: Marisol Perez-Toledo
Author: Aleksandra Jasiulewicz
Author: Gemma D. Banham
Author: Maddy L. Newby
Author: Sian E. Faustini
Author: Alex G. Richter
Author: Haresh Selvaskandan
Author: Roseanne E. Billany
Author: Sherna F. Adenwalla
Author: Ian R. Henderson
Author: Max Crispin ORCID iD
Author: Matthew Graham-Brown
Author: Lorraine Harper
Author: Adam F. Cunningham

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×